The ReadoutDrug pricing at the DNC & when to cut a treatment loose By Damian Garde and Meghana Keshavan July 26, 2016 Reprints Alex Hogan/STAT The Readout for July 26, 2016 About the Authors Reprints Damian Garde National Biotech Reporter Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast. [email protected] @damiangarde Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. [email protected] @megkesh
The Readout Meghana Keshavan Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
The Readout Damian Garde Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
The Readout Damian Garde Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
The Readout Damian Garde How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga
The Readout Meghana Keshavan Aduhelm’s impact on Medicare, a new CRISPR therapy, & a Warp Speed retirement
